Navigation Links
Gene Tests to Identify Ovarian Cancer Have Little Clinical Value

Many genomic tests that are currently used to diagnose and guide treatment of ovarian cancer are not shown to decrease the number of women who die from the disease or improve their quality of life, //according to a new evidence report supported by a partnership of the Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention’s Division of Cancer Prevention and Control, and CDC’s National Office of Public Health Genomics.

Ovarian cancer causes more deaths than any other cancer of the female reproductive system. More than 20,000 women are diagnosed with the disease annually, and approximately 15,000 die from it. The risk for ovarian cancer increases with age and most often is diagnosed in white women over the age of 50. If diagnosed during stage I, ovarian cancer has a survival rate of over 90 percent. However, most cases are diagnosed in advanced stages, when the cancer has spread to other organs.

Physical exams, ultrasounds, and other routine screening efforts for reducing the number of women affected by the disease, and in turn the number who die from it, have been unsuccessful compared with similar efforts aimed at other causes of cancer deaths in women. Because current strategies have not proven to be effective, there is tremendous interest in identifying the disease in its earliest stages by looking at genes, gene expression levels, proteins, and tumor markers. These tests focus on (1) detecting a gene-based tumor marker, such as CA-125, or (2) identifying genetic mutations such as BRCA1 and BRCA2 that indicate increased risk for developing cancer, or (3) identifying genetic changes that predict response to therapy in women with ovarian cancer.

Researchers performed a comprehensive review of the literature and found few studies evaluated genetic tests other than CA-125 or BRCA1 and BRCA2 to diagnose ovarian cancer or identify women at risk. Among the tests evaluated in the report, the researche rs found no studies showing that changing treatment based on test results reduced deaths or improved quality of life in women who were diagnosed with ovarian cancer. There are few data on the harms of gene-based tests for ovarian cancer, including the psychological impact of false-positive tests or delays in treatment that can result from a false-negative test.

A computer simulation model developed by the research team suggests that screening, even with the highly accurate tests, will not result in large reductions in deaths from ovarian cancer unless testing is very frequent (less than 1 year between tests). However, such frequent screening would also yield a large number of false-positive test results. The team stated that research aimed at improving treatment options and the discovery of treatment, lifestyle, or dietary choices that could prevent ovarian cancer would likely offer greater promise for major reductions in deaths from the disease.

"Ovarian cancer and its effects can be devastating for women diagnosed with the disease. The findings from this report will help to guide further research aimed at better treatment that may lead to fewer deaths from ovarian cancer," said Jean R. Slutsky, Director of AHRQ’s Center for Outcomes and Evidence.

This report is the first of a series of five evidence reports that are part of an inter-agency collaboration between AHRQ and CDC. As part of the CDC-supported Evaluation of Genomic Applications in Practice and Prevention (EGAPP) project, the EGAPP working group will evaluate the evidence presented in the report and make recommendations in the near future about the use of these tests for screening, diagnosis, and treatment of ovarian cancer. Other evidence reports requested by EGAPP will evaluate the use of genetic tests for specific diseases or conditions, such as determining an individual patient’s response to drugs used in the treatment of depression.

"This first-ever col laboration of the CDC’s cancer and genomics programs with AHRQ provides important evidence-based guidance to inform both public health and medical practitioners about the appropriate use of genetic testing in cancer prevention and control," said Janet Collins, Ph.D., Director of CDC’s National Center for Chronic Disease Prevention and Health Promotion.

Source-NewswiseSRM
'"/>




Related medicine news :

1. The Effectiveness Of Screening Tests Questioned
2. Blood Tests Can Help Detect Osteoporosis Early In Life
3. Easier Tests To Detect Tuberculosis
4. Fragile X-Associated Tremor /Ataxia Syndrome Need Guidelines For Diagnostic Tests
5. Genetic Tests Could Become As Affordable As Blood Tests
6. Obese Adults Undergo Less Medical Tests And More Vulnerable To Diseases
7. Delay in Breast Cancer Gene Tests
8. Health Officials Inquire Into OraQuick HIV Tests
9. Move to make HIV Tests mandatory For Soldiers In Northeast
10. Punjab Government To Clamp Down On Sex Determination Tests
11. Free HIV Tests Brings Crowd to the Testing Centers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America proudly introduces ... an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start and programmed-start ... 50,000 hour rated lamps utilize the existing electronic ballast, saving labor and maintenance ...
(Date:4/28/2017)... ... April 28, 2017 , ... Children and adolescents who ... experiences than children in the general population. That’s because foster care is designed ... family challenges. While no fault of their own, youth who have experienced trauma ...
(Date:4/28/2017)... Yorba Linda, Ca (PRWEB) , ... April 28, ... ... entities with cardiac or hERG liability could substantially improve drug safety and minimize ... will be provided for validating ion channel inhibition using cell lines and for ...
(Date:4/28/2017)... ... ... Overseer at The House of Yahweh in Abilene, Texas, has published a new post that ... Yisrayl says with so many titles and names for the Creator, it’s hard for many ... Scripture, backed with a lot of research, the truth is undeniable. , “If you ...
(Date:4/28/2017)... ... April 28, 2017 , ... Intellitec Solutions ... Grove Foundation implement a Microsoft Dynamics GP solution that integrates to their PointClickCare ... that specializes in long-term care, Brooke Grove now has the capability to achieve ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)...  CVS Pharmacy, the retail division of CVS ... design to enhance the retail customer experience with ... and expanded beauty selections paired with informational signage ... offerings. Together with its innovative digital programs, these ... experience at CVS Pharmacy.  "Pharmacy ...
(Date:4/20/2017)... 20, 2017 Research and Markets has ... Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, ... their offering. ... pharmacogenomics market was valued at US$ 7,167.6 Mn in 2015, ... expanding at a CAGR of 5.6% from 2016 to 2024. ...
(Date:4/20/2017)... Research and Markets has announced the ... Market Analysis By Service (Manufacturing, Research), By Country, (Brazil, Mexico, ... report to their offering. ... The Latin American pharmaceutical contract manufacturing services market ... Low drug registration cost in Latin American countries and ...
Breaking Medicine Technology: